Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00151515 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss
A Phase 3 study of Androgenetic Alopecia, sponsored by Johnson & Johnson Consumer and Personal Products Worldwide.
- Completed
- Registry status
- Phase 3
- Development phase
- 352
- Enrollment target
- 15
- Study locations
NCT00151515 is a Phase 3 study of Androgenetic Alopecia that has completed, run by Johnson & Johnson Consumer and Personal Products Worldwide. The registered enrollment target is 352 participants, above the 143-participant average among 16 other Androgenetic Alopecia trials with a reported enrollment target (146% higher). The trial reports 15 study locations across 10 states.
The verdict
NCT00151515, a Phase 3 study of Androgenetic Alopecia, has completed, sponsored by Johnson & Johnson Consumer and Personal Products Worldwide.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 352 participants
- Enrollment target
- 15
- Study locations
Study Summary
The primary purpose of the study is to evaluate the efficacy of a topical 5% minoxidil formulation in males for the treatment of pattern hair loss. The secondary purpose is to evaluate the safety of a topical 5% minoxidil formulation in males when used twice daily for the treatment of pattern hair loss and to obtain the safety data on the investigational product when used twice daily for up to one year.
Conditions Studied
Interventions
- DRUG minoxidil
Study Locations (15)
California
- Pfizer Investigational Site - La Jolla
- Pfizer Investigational Site - San Francisco
- Pfizer Investigational Site - Vallejo
Minnesota
- Pfizer Investigational Site - Fridley
- Pfizer Investigational Site - Minneapolis
Ohio
- Pfizer Investigational Site - Cincinnati
- Pfizer Investigational Site - Cleveland
Texas
- Pfizer Investigational Site - Austin
- Pfizer Investigational Site - Dallas
Colorado
- Pfizer Investigational Site - Denver
Connecticut
- Pfizer Investigational Site - New Haven
North Carolina
- Pfizer Investigational Site - Durham
Oregon
- Pfizer Investigational Site - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 352 participants |
| Start Date | 2003-10 |
| Est. Completion | 2004-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00151515
The ClinicalTrials.gov registry entry for NCT00151515 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 352 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 143-participant average among 16 other Androgenetic Alopecia trials with a reported enrollment target (146% higher). The listed sponsor is Johnson & Johnson Consumer and Personal Products Worldwide, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Androgenetic Alopecia appearing as the primary indexed condition, and to 1 intervention - of which minoxidil is the first listed.
NCT00151515 reports 15 study locations spanning 10 distinct geographic areas - top geographies include California, Minnesota, Ohio.
Frequently Asked Questions
What is clinical trial NCT00151515 about?
NCT00151515 is a clinical study titled "A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss". The primary purpose of the study is to evaluate the efficacy of a topical 5% minoxidil formulation in males for the treatment of pattern hair loss. The secondary purpose is to evaluate the safety of a topical 5% minoxidil formulation in males when used twice daily for the treatment of pattern hair l...
What is the current status of trial NCT00151515?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 352 participants. The study started on 2003-10. Estimated completion is 2004-07.
What conditions does trial NCT00151515 study?
This clinical trial studies the following conditions: Androgenetic Alopecia.
What interventions are being tested in trial NCT00151515?
The interventions under investigation include: minoxidil (DRUG).
Who is sponsoring clinical trial NCT00151515?
This trial is sponsored by Johnson & Johnson Consumer and Personal Products Worldwide, which has 26 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00151515 being conducted?
This trial has 15 study locations across California, Colorado, Connecticut, Minnesota, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Androgenetic Alopecia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)
RECRUITING · Phase 3
-
Safety and Efficacy of VDPHL01 in Males With AGA
ACTIVE NOT RECRUITING · Phase 3
-
Sham LaserCap vs. LaserCap SD vs. LaserCap HD+
RECRUITING · NA
-
1470nm Laser for the Treatment of Androgenetic Alopecia and Scarring Alopecia
RECRUITING · NA
-
Safety and Efficacy of VDPHL01 in Males and Females With AGA
ACTIVE NOT RECRUITING · Phase 2
-
Use of Botulinum Toxin in the Treatment of Androgenic Alopecia
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.